799 results on '"Distler, J"'
Search Results
102. S.8.1 An immunochip-based interrogation of scleroderma susceptibility variants
103. S.6.1 β-catenin is a central mediator in SSc
104. S.6.1 β-catenin is a central mediator in SSc
105. Heart involvement in patients with systemic sclerosis is mimicked by Fra-2 transgenic mice
106. Evaluation of Nuclear Receptor Stimulation as a New Option for Cardiac Transplant Vasculopathy Prevention
107. Delayed Therapy with Receptor Tyrosine Kinase Inhibitor Nintedanib Diminished Chronic Rejection in a Murine Lung Transplant Model
108. Evidence of the Contribution of the X Chromosome to Systemic Sclerosis Susceptibility: Association With the Functional Irak1 196Phe/532Ser Haplotype
109. Association of the CD226 Ser307variant with systemic sclerosis: Evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis
110. NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis
111. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
112. SAT0342 INNATE LYMPHOID CELLS ARE PREDICTORS OF DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS: A 3-YEARS FOLLOW-UP STUDY
113. OP0141 HIGH DIMENSIONAL ANALYSIS REVEAL A NETWORK OF CERTAIN TRANSCRIPTION FACTORS THAT LINK VASCULOPATHY AND ORGAN FIBROSIS IN SYSTEMIC SCLEROSIS
114. OP0142 FIBROBLAST GROWTH FACTOR RECEPTOR 3 REGULATES THE ACTIVITY OF PROFIBROTIC CYTOKINE AND GROWTH FACTOR PATHWAYS TO DRIVE FIBROBLAST ACTIVATION AND TISSUE FIBROSIS IN SYSTEMIC SCLEROSIS
115. SAT0284 EPIGENETIC DEREGULATION OF AUTOPHAGY PROMOTES FIBROSIS IN SYSTEMIC SCLEROSIS
116. OP0115 EFFECT OF NINTEDANIB ON PROGRESSION OF INTERSTITIAL LUNG DISEASE (ILD) IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED ILDS: FURTHER DATA FROM THE INBUILD TRIAL
117. AB0150 ADAPTOR PROTEINS ACTIVATE FIBROBLASTS IN SYSTEMIC SCLEROSIS
118. OP0135 INHIBITION OF HSP90 REDUCES PROGRESSION OF DERMAL FIBROSIS AND INDUCES REGRESSION OF ESTABLISHED EXPERIMENTAL DERMAL FIBROSIS INDUCED BY BLEOMYCIN
119. SAT0291 THE ROLE OF X-LINKED INHIBITOR OF APOPTOSIS PROTEIN (XIAP) IN SYSTEMIC SCLEROSIS
120. SAT0302 INNATE LYMPHOID CELLS INDUCE A FIBROTIC PHENOTYPE OF FIBROBLASTS
121. SAT0157 NINTEDANIB DOSE ADJUSTMENTS AND ADVERSE EVENTS IN PATIENTS WITH PROGRESSIVE AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES IN THE INBUILD TRIAL
122. SAT0354 TYPE 3 INNATE LYMPHOID CELLS ARE KEY DRIVERS OF PSORIATIC ARTHRITIS
123. OP0195 VASCULARIZED THREE-DIMENSIONAL MODELS OF HUMAN SKIN FIBROSIS
124. AB0172 PGC-1Α REGULATES AUTOPHAGY TO PROMOTE FIBROBLAST ACTIVATION AND TISSUE FIBROSIS
125. FRI0262 INCREASED PLASMA LEVELS OF HSP90 ARE ASSOCIATED WITH MORE SEVERE LUNG AND SKIN INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS
126. AB1346-HPR REAL-WORLD EFFECTIVENESS AND PERCEIVED USEFULNESS OF SYMPTOM CHECKERS IN RHEUMATOLOGY: INTERIM REPORT FROM THE PROSPECTIVE MULTICENTER BETTER STUDY
127. SAT0287 AMPLIFICATION OF THE PRO-FIBROTIC JAK2-STAT3 SIGNALING AXIS BY TGFΒ-INDUCED EPIGENETIC SILENCING OF SOCS3
128. The Canonical Wnt Pathway in the Pathogenesis of Cardiac Allograft Vasculopathy
129. Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population
130. Association of a KCNA5 gene polymorphism with systemic sclerosis–associated pulmonary arterial hypertension in the European Caucasian population
131. Functional autoantibodies against serpin E2 in rheumatoid arthritis
132. Interleukin-1 is essential for systemic inflammatory bone loss
133. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies
134. Cloning and transcriptional analysis of the rplKA-or f31-rplJL gene cluster of Streptomyces griseus
135. BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4
136. Overview of pathogenesis of systemic sclerosis
137. Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis
138. EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells
139. Imatinib as a novel therapeutic approach for fibrotic disorders
140. Vascularized Three-Dimensional Models of Human Skin Fibrosis
141. Nintedanib dose adjustments and adverse events in patients with progressive autoimmune disease-related interstitial lung diseases in the inbuild trial
142. Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints
143. Mechanisms of vascular damage in SSc—implications for vascular treatment strategies
144. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis
145. Criteria to select molecular targets for anti-fibrotic therapy
146. Eotaxin-3 is involved in Churg–Strauss syndrome – a serum marker closely correlating with disease activity
147. Selective p38MAPK isoform expression and activation in antineutrophil cytoplasmatic antibody-associated crescentic glomerulonephritis: role of p38MAPKα
148. Angiogenesis and vasculogenesis in systemic sclerosis
149. Long term outcomes of immunmodulatory drugs in SSc-ILD - data rom the German SSc network
150. Does anti-acid treatment influence disease progression in SSc-ILD? Data form the German SSc-network
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.